SNTI Stock Risk & Deep Value Analysis
Senti Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SNTI Stock
We analyzed Senti Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SNTI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SNTI Risk Analysis & Red Flags
What Could Go Wrong
The company faces immediate and severe financial distress with an extremely limited cash runway. If Senti Biosciences fails to secure substantial funding in the very near term, it will likely lead to bankruptcy or massive shareholder dilution, effectively wiping out the current investment regardless of the underlying technology's potential.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Extremely limited cash runway and high burn rate.
- ⚠
Micro-cap valuation of $0.02B despite innovative technology.
- ⚠
Heavy reliance on future capital raises that will likely be highly dilutive.
- ⚠
No clear path to profitability or positive free cash flow in the near-to-medium term.
Upcoming Risk Events
- 📅
Failure to secure critical funding, leading to bankruptcy or severe dilution
- 📅
Negative or inconclusive clinical trial results for SENTI-202
- 📅
Increased competitive pressure in synthetic biology/gene therapy
- 📅
Further reverse stock splits or delisting concerns
When to Reconsider
- 🚪
Failure to announce new funding within the next 3 months.
- 🚪
Any announcement of significant, unfavorable clinical data for SENTI-202.
- 🚪
Further share dilution events that are not coupled with significant pipeline progress.
- 🚪
Trading volume dries up, indicating loss of market interest.
Unlock SNTI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Senti Biosciences Inc (SNTI) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
34
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit Senti Biosciences Inc WebsiteInvestment Thesis
Senti Biosciences offers an exceptionally high-risk, high-reward opportunity based on its innovative gene circuit platform, which could revolutionize cell and gene therapies. While facing critical financial challenges, success in securing immediate funding and achieving early clinical milestones for SENTI-202 could rapidly re-rate the stock, offering multi-bagger returns for investors with an aggressive risk appetite willing to stomach potential total loss.
Is SNTI Stock Undervalued?
Unlock the full AI analysis for SNTI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SNTI Price Targets & Strategy
12-Month Target
$2.50
Bull Case
$5.00
Bear Case
$0.10
Valuation Basis
Target represents a speculative re-rating to a $60M market cap (3x current) upon successful near-term funding and initial clinical progress, assuming minimal further dilution from current levels.
Entry Strategy
Highly speculative; for aggressive investors only. Consider dollar-cost averaging below $0.80 if clear funding pathway emerges, or on any significant positive news indicating financial stabilization.
Exit Strategy
Take profit on any significant rallies above $2.00 driven by news; hard stop-loss if price falls below $0.50 without positive catalysts.
Portfolio Allocation
1-3% for aggressive risk tolerance only, as a highly speculative satellite position.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SNTI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable (The underlying technology's potential remains, but financial instability risks erosion)
Moat Sources
1 Identified
The moat's durability hinges entirely on successful clinical validation of its gene circuit technology and robust patent protection. Without adequate funding to advance its pipeline, the potential moat remains theoretical and highly vulnerable to competitors' progress.
Moat Erosion Risks
- •Failure to adequately fund R&D and clinical trials, allowing competitors to gain lead.
- •Intellectual property challenges or expiration.
- •Technological obsolescence if superior gene editing/circuitry methods emerge.
- •Failure of platform to translate from preclinical to clinical efficacy.
SNTI Competitive Moat Analysis
Sign up to see competitive advantages
SNTI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Highly speculative due to financial distress, volatile retail interest on low float and price)
Institutional Sentiment
Negative (Lack of institutional interest due to extreme risk and financial instability)
Insider Activity (Form 4)
No significant recent insider buying activity reported in provided context; risk of future selling or dilution by insiders if funding is secured.
Options Flow
Normal options activity (Limited options available for micro-cap, highly speculative shares; any activity is likely retail-driven and volatile).
Earnings Intelligence
Next Earnings
Estimated mid-May 2026 (for Q1 2026 results)
Surprise Probability
Low (Focus is on cash position and pipeline updates, not traditional EPS/revenue beats)
Historical Earnings Pattern
Highly volatile reactions to financial updates; tends to sell off on signs of cash depletion or lack of progress, but could see significant short-term spikes on funding or clinical news.
Key Metrics to Watch
Competitive Position
Top Competitor
CRSP (CRISPR Therapeutics)
Market Share Trend
Not applicable; too early stage. SNTI aims to create new market segments or sub-segments rather than capture existing share.
Valuation vs Peers
SNTI trades at a deep discount to established gene/cell therapy peers on every metric (e.g., P/S, EV/Pipeline), primarily due to its severe financial distress and early-stage development.
Competitive Advantages
- •Proprietary gene circuit engineering platform for cell and gene therapies.
- •Potential for highly precise and tunable therapeutic control mechanisms.
- •Broad applicability of platform across various disease areas (e.g., oncology, immunology).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SNTI Stock Higher?
Near-Term (0-6 months)
- •Announcement of significant dilutive or non-dilutive funding (Critical, within 0-3 months)
- •Initiation of SENTI-202 Phase 1 clinical trial
Medium-Term (6-18 months)
- •Early safety and/or efficacy data from SENTI-202 Phase 1 trial
- •New strategic research and development partnership announcement
- •Advancement of additional pipeline candidates towards IND
Long-Term (18+ months)
- •Positive Phase 2/3 clinical trial data for lead candidates leading to regulatory approval
- •Broad platform validation across multiple therapeutic areas
- •Acquisition interest from larger pharmaceutical companies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SNTI?
- ✓
Announcement of new significant funding or capital raises.
- ✓
Positive clinical trial updates or regulatory designations for SENTI-202.
- ✓
Formation of new major strategic partnerships or collaborations.
- ✓
Significant insider buying activity.
Bull Case Analysis
See what could go right with Premium
Competing with SNTI
See how Senti Biosciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Senti Biosciences Inc SNTI | — | 2.0 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Senti Biosciences Inc (SNTI)?
As of March 27, 2026, Senti Biosciences Inc has a DVR Score of 2.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Senti Biosciences Inc use?
SNTI is the ticker symbol for Senti Biosciences Inc. The company trades on the NCM.
What is the risk level for SNTI stock?
Our analysis rates Senti Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SNTI DVR analysis updated?
Our AI-powered analysis of Senti Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 27, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SNTI (Senti Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.